Adam M Lee1, Qian Shi1, Emily Pavey1, Steven R Alberts1, Daniel J Sargent1, Frank A Sinicrope1, Jeffrey L Berenberg1, Richard M Goldberg1, Robert B Diasio2. 1. Department of Molecular Pharmacology and Experimental Therapeutics (AML, RBD), Alliance Statistics and Data Center (QS, EP, DJS), Division of Medical Oncology (SRA, FAS, RBD), Division of Gastroenterology (FAS), Mayo Clinic Cancer Center, Rochester, MN; Cancer Prevention and Control Program, University of Hawaii Cancer Center, Honolulu, HI (JLB); Division of Medical Oncology, The Ohio State University Medical Center, Columbus, OH (RMG). 2. Department of Molecular Pharmacology and Experimental Therapeutics (AML, RBD), Alliance Statistics and Data Center (QS, EP, DJS), Division of Medical Oncology (SRA, FAS, RBD), Division of Gastroenterology (FAS), Mayo Clinic Cancer Center, Rochester, MN; Cancer Prevention and Control Program, University of Hawaii Cancer Center, Honolulu, HI (JLB); Division of Medical Oncology, The Ohio State University Medical Center, Columbus, OH (RMG). diasio.robert@mayo.edu.
Abstract
BACKGROUND: Previous studies have suggested the potential importance of three DPYD variants (DPYD*2A, D949V, and I560S) with increased 5-FU toxicity. Their individual associations, however, in 5-FU-based combination therapies, remain controversial and require further systematic study in a large patient population receiving comparable treatment regimens with uniform clinical data. METHODS: We genotyped 2886 stage III colon cancer patients treated adjuvantly in a randomized phase III trial with FOLFOX or FOLFIRI, alone or combined with cetuximab, and tested the individual associations between functionally deleterious DPYD variants and toxicity. Logistic regressions were used to assess univariate and multivariable associations. All statistical tests were two-sided. RESULTS: In 2594 patients with complete adverse event (AE) data, theincidence of grade 3 or greater 5FU-AEs in DPYD*2A, I560S, and D949V carriers were 22/25 (88.0%), 2/4 (50.0%), and 22/27 (81.5%), respectively. Statistically significant associations were identified between grade 3 or greater 5FU-AEs and both DPYD*2A (odds ratio [OR] = 15.21, 95% confidence interval [CI] = 4.54 to 50.96, P < .001) and D949V (OR = 9.10, 95% CI = 3.43 to 24.10, P < .001) variants. Statistical significance remained after adjusting for multiple variables. The DPYD*2A variant statistically significantly associated with the specific AEs nausea/vomiting (P = .007) and neutropenia (P < .001), whereas D949V statistically significantly associated with dehydration (P = .02), diarrhea (P = .003), leukopenia (P = .002), neutropenia (P < .001), and thrombocytopenia (P < .001). Although two patients with I560S had grade≥3 5FU-AEs; a statistically significant association could not be demonstrated because of its low frequency (P = .48). CONCLUSION: In the largest study to date, statistically significant associations were found between DPYD variants (DPYD*2A and D949V) and increased incidence of grade 3 or greater 5FU-AEs in patients treated with adjuvant 5-FU-based combination chemotherapy.
RCT Entities:
BACKGROUND: Previous studies have suggested the potential importance of three DPYD variants (DPYD*2A, D949V, and I560S) with increased 5-FUtoxicity. Their individual associations, however, in 5-FU-based combination therapies, remain controversial and require further systematic study in a large patient population receiving comparable treatment regimens with uniform clinical data. METHODS: We genotyped 2886 stage III colon cancerpatients treated adjuvantly in a randomized phase III trial with FOLFOX or FOLFIRI, alone or combined with cetuximab, and tested the individual associations between functionally deleterious DPYD variants and toxicity. Logistic regressions were used to assess univariate and multivariable associations. All statistical tests were two-sided. RESULTS: In 2594 patients with complete adverse event (AE) data, the incidence of grade 3 or greater 5FU-AEs in DPYD*2A, I560S, and D949V carriers were 22/25 (88.0%), 2/4 (50.0%), and 22/27 (81.5%), respectively. Statistically significant associations were identified between grade 3 or greater 5FU-AEs and both DPYD*2A (odds ratio [OR] = 15.21, 95% confidence interval [CI] = 4.54 to 50.96, P < .001) and D949V (OR = 9.10, 95% CI = 3.43 to 24.10, P < .001) variants. Statistical significance remained after adjusting for multiple variables. The DPYD*2A variant statistically significantly associated with the specific AEs nausea/vomiting (P = .007) and neutropenia (P < .001), whereas D949V statistically significantly associated with dehydration (P = .02), diarrhea (P = .003), leukopenia (P = .002), neutropenia (P < .001), and thrombocytopenia (P < .001). Although two patients with I560S had grade≥3 5FU-AEs; a statistically significant association could not be demonstrated because of its low frequency (P = .48). CONCLUSION: In the largest study to date, statistically significant associations were found between DPYD variants (DPYD*2A and D949V) and increased incidence of grade 3 or greater 5FU-AEs in patients treated with adjuvant 5-FU-based combination chemotherapy.
Authors: André B P van Kuilenburg; Doreen Dobritzsch; Rutger Meinsma; Janet Haasjes; Hans R Waterham; Malgorzata J M Nowaczyk; George D Maropoulos; Guido Hein; Hermann Kalhoff; Jean M Kirk; Holger Baaske; Anne Aukett; John A Duley; Kate P Ward; Ylva Lindqvist; Albert H van Gennip Journal: Biochem J Date: 2002-05-15 Impact factor: 3.857
Authors: Jeff A Sloan; Richard M Goldberg; Daniel J Sargent; Delfino Vargas-Chanes; Suresh Nair; Steven S Cha; Paul J Novotny; Michael A Poon; Michael J O'Connell; Charles L Loprinzi Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: Richard M Goldberg; Daniel J Sargent; Roscoe F Morton; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Henry C Pitot; Steven R Alberts Journal: J Clin Oncol Date: 2003-12-09 Impact factor: 44.544
Authors: P Thirion; S Michiels; J P Pignon; M Buyse; A C Braud; R W Carlson; M O'Connell; P Sargent; P Piedbois Journal: J Clin Oncol Date: 2004-09-15 Impact factor: 44.544
Authors: Komal P Singh; Anand A Dhruva; Elena Flowers; Kord M Kober; Christine Miaskowski Journal: Crit Rev Oncol Hematol Date: 2017-11-20 Impact factor: 6.312
Authors: Bart A W Jacobs; Nikol Snoeren; Morsal Samim; Hilde Rosing; Niels de Vries; Maarten J Deenen; Jos H Beijnen; Jan H M Schellens; Miriam Koopman; Richard van Hillegersberg Journal: Eur J Clin Pharmacol Date: 2018-02-11 Impact factor: 2.953
Authors: Shikshya Shrestha; Erin E Tapper; Colbren Scout Trogstad-Isaacson; Timothy J Hobday; Steven M Offer; Robert B Diasio Journal: JCO Precis Oncol Date: 2018-10-03
Authors: Shikshya Shrestha; Cheng Zhang; Calvin R Jerde; Qian Nie; Hu Li; Steven M Offer; Robert B Diasio Journal: Clin Pharmacol Ther Date: 2018-02-02 Impact factor: 6.875
Authors: Q Nie; S Shrestha; E E Tapper; C S Trogstad-Isaacson; K J Bouchonville; A M Lee; R Wu; C R Jerde; Z Wang; P A Kubica; S M Offer; R B Diasio Journal: Clin Pharmacol Ther Date: 2017-05-26 Impact factor: 6.875
Authors: Rentian Wu; Qian Nie; Erin E Tapper; Calvin R Jerde; Garrett S Dunlap; Shikshya Shrestha; Tarig A Elraiyah; Steven M Offer; Robert B Diasio Journal: Cancer Res Date: 2016-08-30 Impact factor: 12.701
Authors: Adam M Lee; Qian Shi; Steven R Alberts; Daniel J Sargent; Frank A Sinicrope; Jeffrey L Berenberg; Axel Grothey; Blase Polite; Emily Chan; Sharlene Gill; Morton S Kahlenberg; Suresh G Nair; Anthony F Shields; Richard M Goldberg; Robert B Diasio Journal: Pharmacogenet Genomics Date: 2016-03 Impact factor: 2.089
Authors: Ursula Amstutz; Linda M Henricks; Steven M Offer; Julia Barbarino; Jan H M Schellens; Jesse J Swen; Teri E Klein; Howard L McLeod; Kelly E Caudle; Robert B Diasio; Matthias Schwab Journal: Clin Pharmacol Ther Date: 2017-11-20 Impact factor: 6.875